Skip to content

Daratumumab exposure and time-dependent clearance

Two-compartment physical PK realized from the authors' executed simulation code, with linear and time-declining saturable elimination on the central amount, explicit infusions and separate loss accounting.

Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

How do fixed daratumumab amounts change central exposure?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

Single 4 mg/kg reference projection

Conditional physical PK projection with fixed covariates and explicitly authored administrations.

0–2 day

Scenario details

Single 4 mg/kg reference projection

Conditional physical PK projection with fixed covariates and explicitly authored administrations.

Readouts

Central concentration · mg/L
Central concentration over the selected simulation window.
Exposure (AUC) · mg*day/L
Exposure (AUC) over the selected simulation window.
Maximum elimination rate · mg/day
Maximum elimination rate over the selected simulation window.
Total eliminated · mg
Total eliminated over the selected simulation window.

Study purpose

  • How do the model's key biological readouts change under single 4 mg/kg reference projection?

Assumptions

  • Physical PK realization of the authors' executed simulation code: two compartments, linear loss and a time-declining saturable elimination applied to the central amount, with time in days, amounts mg and concentrations mg/L.
  • The supplied coefficient realization uses CL = .1 L/day, Q = 1.54 L/day, VM0 = 49.92 mg/day and kdes = .0312/day. These are model inputs, not newly estimated clinical parameters.
  • Saturable elimination is VM0 exp(-kdes elapsed) Acentral/(KM+Acentral), with KM = 0.93 mg applied to the central amount. This is a conditional executed-code coefficient realization; no explicit receptor or occupancy states are present.
  • Covariates are fixed, individual deviations and residual noise are zero. Dose amounts and weight are frozen together in each context.
  • First, second and later infusion durations are 7 h, 4.3 h and 3.4 h. Nominal calendars and split-first-dose examples are authored fixed realizations, without random jitter or synthetic cohort replay.
  • Short 14-day windows end predose at the day 14 administration; an infusion beginning at the endpoint contributes no exposure within that window.
  • Elapsed treatment time starts at zero. Shifted starts require a consistent prior drug history and treatment-clock initialization.
  • Neural training, fine-tuned patient prediction, optimized dosing, original clinical data and reported neural performance are not reconstructed.
  • A saturation rate factor is not CD38 receptor occupancy or an independently validated clinical target.

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Simulation time
day
day
2 → 168

Time between reported samples.

day
0.05 → 1

2 changes · Variation 1

Continue in the background and keep the result.

Biology

Explore daratumumab dose, covariate and infusion effects under an explicit physical PK projection.

Explore daratumumab dose, covariate and infusion effects under an explicit physical PK projection.

Model details

16 parameters · 6 states · 6 equations · 18 derived outputs

Classification & API access
Therapeutic
Daratumumab
Modality
Monoclonal antibody
Target
CD38
Disease / scope
Multiple myeloma reference PK
ParameterDefaultUnitDescription
Albumin clearance poweralbumin_cl_power-1.149—Frozen primary-parameter projection; physical day-coordinate convention and explicit covariate formula.
Serum albuminalbumin_g_l37g/LFrozen primary-parameter projection; physical day-coordinate convention and explicit covariate formula.
Clearance referencecl_reference_l_day0.1L/dayFrozen primary-parameter projection; physical day-coordinate convention and explicit covariate formula.
Female flagfemale_flag0—Frozen primary-parameter projection; physical day-coordinate convention and explicit covariate formula.
Female central distribution volume fractionfemale_vc_fraction-0.205—Frozen primary-parameter projection; physical day-coordinate convention and explicit covariate formula.
Igg clearance fractionigg_cl_fraction0.806—Frozen primary-parameter projection; physical day-coordinate convention and explicit covariate formula.
Igg myeloma flagigg_myeloma_flag0—Frozen primary-parameter projection; physical day-coordinate convention and explicit covariate formula.
Kdeskdes_per_day0.03121/dayFrozen primary-parameter projection; physical day-coordinate convention and explicit covariate formula.
Km amountkm_amount_mg0.93mgMichaelis amount scale for central drug amount in the conditional executed-code realization.
Intercompartmental clearanceq_l_day1.54L/dayFrozen primary-parameter projection; physical day-coordinate convention and explicit covariate formula.
Central distribution volume referencevc_reference_l4.09LFrozen primary-parameter projection; physical day-coordinate convention and explicit covariate formula.
VM0vm0_mg_day49.92mg/dayFrozen primary-parameter projection; physical day-coordinate convention and explicit covariate formula.
Peripheral distribution volumevp_l3.06LFrozen primary-parameter projection; physical day-coordinate convention and explicit covariate formula.
Weight clearance powerweight_cl_power0.451—Frozen primary-parameter projection; physical day-coordinate convention and explicit covariate formula.
Weightweight_kg78.6kgFrozen primary-parameter projection; physical day-coordinate convention and explicit covariate formula.
Weight central distribution volume powerweight_vc_power0.375—Frozen primary-parameter projection; physical day-coordinate convention and explicit covariate formula.

Related models

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics